Science 37, Inc. ((SNCE)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The study titled Evaluation of Oscillation and Lung Expansion (OLE) Using The Volara® System for Treatment of Respiratory Complications in Patients With Neuromuscular Disease in the Home Setting aimed to assess the efficacy of OLE therapy in managing respiratory issues in neuromuscular disease patients. This non-randomized, open-label pilot study compared patient outcomes during a retrospective control period and an active treatment period, focusing on the frequency of pulmonary exacerbations and healthcare utilization.
The intervention tested was the Oscillation and Lung Expansion (OLE) therapy, a device-based treatment designed to aid airway clearance through continuous high-frequency oscillation and positive expiratory pressure.
The study was designed as a single-group interventional trial where participants served as their own controls. It involved no masking, and the primary purpose was treatment. Data collection occurred in patients’ homes, emphasizing real-world applicability.
The study began on November 4, 2021, but was terminated before completion. The last update was submitted on July 30, 2025. These dates are crucial for investors to understand the study’s timeline and its current status.
The termination of this study could impact investor sentiment and stock performance for Baxter Healthcare Corporation and Science 37, Inc. Investors may view the termination as a setback, potentially affecting stock prices negatively. However, the broader industry context, including ongoing research and development in respiratory therapies, may mitigate these effects.
The study has been terminated, and further details can be accessed on the ClinicalTrials portal.